Filana Therapeutics Inc 2026年季度报告

(Mark One)☑QUARTERLY REPORTPURSUANT TO SECTION 13 OR15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026or ☐TRANSITION REPORTPURSUANT TO SECTION 13 OR15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 Filana Therapeutics, Inc.(Exact name of registrant as specified in its charter) (Stateorotherjurisdictionofincorporationororganization) 6801 N. Capital of Texas Highway, Building 1; Suite 300, Austin, TX 78731(512) 501-2444(Address, including zip code, of registrant’s principal executive offices andtelephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: NasdaqCapital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated Filer☐Smaller Reporting Company☑Emerging Growth Company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☑ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. FILANA THERAPEUTICS, INC.TABLE OF CONTENTS Page No.PART I.FINANCIAL INFORMATIONItem 1.Financial StatementsCondensed Consolidated Balance Sheets – March 31, 2026 and December 31, 20253Condensed Consolidated Statements of Operations –Three Months Ended March 31, 2026 and 20254Condensed Consolidated Statements of Changes in Stockholders’Equity - Three Months EndedMarch 31, 2026 and 20255Condensed Consolidated Statements of Cash Flows – ThreeMonths Ended March 31, 2026and 20256Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk27Item 4.Controls and Procedures27PART II.OTHER INFORMATIONItem 1.Legal Proceedings27Item 1ARisk Factors27Item 2.Unregistered Sales of Equity Securities and Use of Proceeds28Item 3.Defaults Upon Senior Securities28Item 4.Mine Safety Disclosures28Item 5.Other Information28Item 6.Exhibits29Signatures302 Table of Contents PART I. FINANCIAL INFORMATION Item 1.Financial Statements FILANA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited, In thousands, except share and par value data) March 31, 2026December 31,2025 FILANA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited, in thousands, except per share data) Three months endedMarch 31,20262025Operating expenses:Research and development$4,544$13,666General and administrative6,62410,920Total operating expenses11,16824,586Operating loss(11,168)(24,586)Interest income7891,265Other income (loss), net48(82)Net loss$(10,331)$(23,403)Net loss per share, basic and diluted$(0.21)$(0.48) FILANA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited, in thousands, except share data) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited, in thousands) Filana Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements(Unaudited) Note 1. General and Liquidity Filana Therapeutics, Inc. and its wholly-owned subsidiary (collectively referred to as the “Company”) discovers and developsproprietary pharmaceutical product candidates that may offer significant improvements to patients and healthcare professionals.The Company currentlyfocuses its discovery and product development efforts on disorders of the nervous system. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordancewith accounting principles generally accepted in the United States (“GAAP”) for interim financial information and pursuant to theinstructions to the Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. All intercompany transactions and balanceshave been elim